KO Pharmacology Research and Drug Discovery Client Plato BioPharma, Inc. Acquired by Inotiv, Inc.

KO Client Plato BioPharma, Inc., a Colorado-based pharmacology research and drug discovery company, has been acquired by leading contract research organization Inotiv, Inc. The KO team, led by partner John Gaddis, represented Plato BioPharma in the acquisition.

Plato BioPharma specializes in cardiovascular, renal, pulmonary and hepatic therapeutic areas, specifically within living organisms (or, “in vivo”). The company is expected to support Inotiv’s growing Boulder, Colo., presence, while also expanding on its in vivo pharmacology offerings.

“This addition allows us to support and accelerate [Plato BioPharma’s] growth plans, while further expanding into more physiologic and pharmacologic offerings, enabling a wider range of clients to make informed decisions with confidence as they move toward their first-in-human clinical goals,” said John Sagartz, DVM, Ph.D., DACVP, Inotiv’s Chief Strategy Officer.

KO attorneys Ian Kuliasha, Michael Wysolmerski and corporate paralegal Krystal Rushton also worked with Gaddis to represent Plato BioPharma in the transaction.

Read more about the acquisition via the Boulder Daily Camera.